SanBio Co., Ltd.

Overview

SanBio Co., Ltd. (サンバイオ株式会社) is a Japanese regenerative medicine company headquartered in Tokyo, Japan, with a primary focus on developing cell therapy medicines for the treatment of neurological disorders and injuries. The company is listed on the Tokyo Stock Exchange (TSE: 4592) and has established itself as a leader in the field of cellular therapeutics for central nervous system (CNS) conditions["@sanbio"].

Overview

SanBio Co., Ltd. (サンバイオ株式会社) is a Japanese regenerative medicine company headquartered in Tokyo, Japan, with a primary focus on developing cell therapy medicines for the treatment of neurological disorders and injuries. The company is listed on the Tokyo Stock Exchange (TSE: 4592) and has established itself as a leader in the field of cellular therapeutics for central nervous system (CNS) conditions["@sanbio"].

SanBio's proprietary cell therapy platform is based on allogeneic (donor-derived) mesenchymal stromal cells (MSCs) that are processed using the company's proprietary methodology to enhance their therapeutic potential. The lead product candidate, SB623, has been evaluated in multiple clinical trials for the treatment of neurological deficits resulting from traumatic brain injury (TBI) and ischemic stroke["@sb623tbi"][@sb623stroke].

The company's mission centers on developing innovative regenerative medicine therapies that restore neurological function and improve quality of life for patients with conditions that currently have limited treatment options. SanBio's approach leverages the natural regenerative capabilities of the human body by harnessing the therapeutic potential of specially processed stem cells["@sanbioa"].

Company Background

Corporate History

SanBio was established in 1999 with a vision to advance regenerative medicine approaches for the treatment of neurological disorders. The company was founded based on research conducted by Professor Hideyuki Okano, a leading figure in regenerative medicine and stem cell biology at Keio University in Tokyo[@sanbio].

Key Milestones:

| Year | Event |
|------|-------|
| 1999 | Company founded in Tokyo |
| 2001 | Initiation of SB623 research program |
| 2005 | Preclinical development begins |
| 2011 | First-in-human clinical trial initiated |
| 2014 | Phase 1/2a trial for TBI initiated |
| 2016 | Phase 2 trial for stroke initiated |
| 2019 | Phase 2 results announced |
| 2021 | Japanese regulatory consultation |
| 2025 | AKUUGO approval for TBI |

Organizational Structure

Corporate Overview:

• Headquarters: Tokyo, Japan
• Stock Exchange: Tokyo Stock Exchange (TSE: 4592)
• Employees: Approximately 200-300
• CEO: Keita Mori
• Founded: 1999

• Keita Mori: President & CEO - Leads corporate strategy and operations
• Professor Hideyuki Okano: Founding Scientific Advisor - Pioneer in iPSC and regenerative medicine research
• Shinya Hirata: Head of R&D - Oversees research and development programs
• Keizo Nakada: Head of Production - Manages manufacturing and quality
• Dr. Damien Bates: Chief Medical Officer - Leads clinical development and medical affairs

• Board of Directors with independent outside directors
• Audit and Supervisory Committee
• Scientific Advisory Board

Business Model

SanBio operates as a specialty regenerative medicine company focused on:

• Development of cell therapy products for neurological conditions
• Manufacturing of cellular products under GMP conditions
• Clinical development through regulatory approval
• Commercialization in Japan and potential international markets

Technology Platform

Mesenchymal Stromal Cell (MSC) Technology

SanBio's technology platform is based on allogeneic mesenchymal stromal cells derived from healthy donor bone marrow. These cells undergo proprietary processing to enhance their therapeutic properties and are administered directly to the affected region of the brain[@msc][@regenerative].

MSC Biology:

Mesenchymal stromal cells are multipotent stem cells that can differentiate into various connective tissue cell types. However, their therapeutic potential in neurological applications is primarily mediated through paracrine signaling rather than direct cell replacement.

Key Properties:

SB623: Lead Product Candidate

SB623 is SanBio's lead product candidate—a population of allogeneic bone marrow-derived mesenchymal stromal cells that are processed using the company's proprietary methodology[@product].

Product Characteristics:

| Property | Description |
|----------|-------------|
| Cell Source | Human bone marrow (allogeneic) |
| Processing | Proprietary methodology |
| Administration | Intracranial implantation |
| Indication | Neurological deficits from TBI/stroke |
| Stage | Clinical development |

Mechanism of Action:

SB623 exerts its therapeutic effects through multiple mechanisms:

• Brain-derived neurotrophic factor (BDNF)
• Glial cell line-derived neurotrophic factor (GDNF)
• Nerve growth factor (NGF)
• Vascular endothelial growth factor (VEGF)[@bdnf][@gdntf]

• Reduce pro-inflammatory cytokines
• Increase anti-inflammatory factors
• Promote regulatory T-cell function[@inflammation]

• Promote angiogenesis
• Support neural progenitor cell function
• Enhance synaptic plasticity

• Anti-apoptotic effects
• Antioxidant properties
• Support mitochondrial function

Proprietary Processing

SanBio's proprietary processing method differentiates SB623 from other MSC-based approaches:

Processing Steps:

Key Advantages:

• Enhanced neurotrophic factor secretion
• Improved survival after implantation
• Consistent product quality
• Scalable manufacturing

Clinical Development Program

Traumatic Brain Injury (TBI)

Phase 1/2a Study

SanBio conducted a Phase 1/2a clinical trial evaluating SB623 in patients with chronic neurological deficits following traumatic brain injury[@sb623tbi].

Study Design:

• Design: Open-label, dose-escalation
• Patients: Adults with chronic motor deficits from TBI (≥12 months post-injury)
• Dose: Multiple dose cohorts
• Administration: Single intracranial implantation

• Safety and tolerability
• Neurological function assessment

• Acceptable safety profile
• Preliminary evidence of neurological improvement
• Dose-response relationship observed

Phase 2 Study

A larger Phase 2 study further evaluated SB623 in TBI patients[@sb623tbi].

Study Design:

• Design: Randomized, double-blind, placebo-controlled
• Patients: Chronic TBI with motor deficits
• Primary Endpoint: Change in motor function scores

• Primary endpoint met in modified analysis
• Clinically meaningful improvements observed
• Durable effects at long-term follow-up

Ischemic Stroke

Phase 2 Study

SanBio initiated a Phase 2 clinical trial evaluating SB623 in patients with chronic neurological deficits from ischemic stroke[@sb623stroke].

Study Design:

• Design: Randomized, double-blind, placebo-controlled
• Patients: Adults with chronic stroke (6-60 months post-stroke)
• Primary Endpoint: Motor function improvement

• Motor recovery measures
• Functional independence
• Quality of life assessments
• Imaging biomarkers

• Enrollment completed
• Results published

Biomarker Research

SanBio has implemented biomarker research to support clinical development:

Biomarkers Studied:

• Neuroimaging (MRI)
• CSF neurotrophic factors
• Inflammatory markers
• Functional outcome measures

• Patient selection and stratification
• Response prediction
• Mechanism of action validation
• Dose selection

Regulatory Status

Japanese Regulatory Pathway

SanBio is pursuing regulatory approval in Japan through the Pharmaceuticals and Medical Devices Agency (PMDA)[@japanreg].

Regulatory Framework:

Japan has established a dedicated regulatory pathway for regenerative medicine products:

AKUUGO® Approval

In December 2025, SanBio received partial change approval for AKUUGO® (SB623) for the treatment of chronic neurological deficits resulting from traumatic brain injury in Japan[@akuugo2025].

Significance:

• First cell therapy product for TBI in Japan
• Validates SanBio's technology platform
• Enables commercialization in Japanese market

International Regulatory Strategy

SanBio is evaluating regulatory strategies for other markets:

Potential Markets:

• United States (FDA)
• European Union (EMA)
• Other Asian markets

• Leverage Japanese approval for international submissions
• Adaptive trial designs for efficiency
• Regulatory pre-submission meetings

Pipeline and Future Programs

Current Pipeline

| Product | Indication | Stage | Status |
|---------|------------|-------|--------|
| SB623 (AKUUGO®) | TBI (chronic) | Approved (Japan) | Launched |
| SB623 | Stroke (chronic) | Phase 2 | Completed |
| Next-generation | Various | Discovery | Preclinical |

Future Development Priorities

Research Programs

Preclinical Programs:

• Enhanced cell formulations
• Combination with pharmacological agents
• Alternative delivery methods

• Molecular mechanisms of action
• Biomarker development
• Patient selection criteria

Scientific Approach

Cell Therapy for CNS Disorders

SanBio's approach to treating neurological disorders represents a paradigm shift from traditional pharmacological interventions[@celltherapy][@neuralrepair].

Rationale:

Traditional drug development for CNS disorders faces significant challenges:

• Blood-brain barrier limits drug delivery
• Complex neuronal circuits difficult to target
• Limited regenerative capacity of adult CNS

• Cells can be administered directly to the brain
• Provide sustained therapeutic signaling
• Activate endogenous repair mechanisms

| Advantage | Description |
|-----------|-------------|
| Paracrine Signaling | Release multiple therapeutic factors |
| Immunomodulation | Reduce harmful inflammation |
| Safety | Established safety profile |
| Scalability | Manufacturing feasibility |
| Allogeneic Use | Off-the-shelf availability |

Mechanisms of Neural Repair

SB623 promotes neural repair through multiple parallel pathways[@nogo][@neuralrepair]:

1. Neurotrophic Support:

The secreted neurotrophic factors support neuron survival and function:

• BDNF: Supports synaptic plasticity and cognitive function
• GDNF: Protects dopaminergic and motor neurons
• NGF: Supports cholinergic neurons and memory

MSCs modulate the immune response:

• Reduce microglial activation
• Shift from pro-inflammatory to anti-inflammatory state
• Create environment favorable for repair

The cells create a permissive environment for regeneration:

• Anti-Nogo effects (promote axon growth)
• Support angiogenesis
• Enhance neural progenitor cell activity

Clinical Experience and Safety

The clinical development program has established a safety profile for SB623:

Safety Findings:

• No serious adverse events related to product
• Intracranial implantation procedures well-tolerated
• No tumor formation observed
• No immune rejection of allogeneic cells

• Post-operative pain
• Headache
• Temporary neurological symptoms

Competitive Landscape

Cell Therapy Competition

SanBio occupies a unique position in the cell therapy landscape for CNS disorders:

| Company | Product | Indication | Stage |
|---------|---------|------------|-------|
| SanBio | SB623 | TBI/Stroke | Phase 2/Approved |
| ReNeuron | CTX0E16 | Stroke | Phase 2 |
| Neuralstem | NSI-566 | ALS | Phase 2 |
| Cytokinetics | Various | Spinal cord injury | Preclinical |

Competitive Advantages

SanBio's competitive position includes:

• Proprietary processing technology
• Allogeneic (off-the-shelf) product
• Strong IP portfolio
• Established safety database
• Japanese regulatory success

Financial Information

Stock and Market Data

Exchange Listing:

• Stock Exchange: Tokyo Stock Exchange
• Ticker: 4592
• Listing Date: 2015

Financial Performance

Revenue and Investment:

• R&D investment significant
• No commercial revenue until AKUUGO launch
• Funding through partnerships and equity

• Clinical trial costs
• Manufacturing infrastructure
• Regulatory activities

Relevance to Neurodegeneration

Connections to Neurodegenerative Disease

While SanBio's current focus is on traumatic brain injury and stroke, the technology has significant relevance to neurodegenerative disease research[@regenerative][@celltherapy].

Relevance to Alzheimer's Disease:

• Neurotrophic factor delivery could support cholinergic neurons
• Immunomodulatory effects may reduce neuroinflammation
• Platform technology adaptable to AD

• GDNF secretion could protect dopaminergic neurons
• Cell therapy approach to motor symptoms
• Potential for disease modification

• Amyotrophic lateral sclerosis (ALS)
• Spinal cord injury
• Multiple sclerosis
• Huntington's disease

Research Contributions

SanBio's research contributes to the broader field of regenerative medicine:

Partnerships and Collaborations

Academic Collaborations

SanBio maintains collaborations with leading Japanese research institutions:

Keio University:

• Founding scientific connection
• Ongoing research collaboration
• Technology access

• National Center of Neurology and Psychiatry
• University research collaborations

Industry Partnerships

SanBio evaluates partnership opportunities for:

• Co-development arrangements
• Manufacturing partnerships
• Commercialization agreements
• International expansion

Government Relationships

Engagement with Japanese regulatory and funding bodies:

• PMDA regulatory discussions
• Ministry of Health support
• Economic development programs

Manufacturing and Operations

GMP Manufacturing

SanBio operates GMP manufacturing facilities for cellular products:

Manufacturing Capabilities:

• Cell culture and expansion
• Quality control testing
• Product characterization
• Fill and finish

• GMP compliance
• Quality management systems
• Regulatory compliance

Supply Chain

Cell Source:

• Healthy donor bone marrow
• Established donor network
• Screening and testing protocols

• Consistent product quality
• Scalable production
• Inventory management

Future Directions

Strategic Vision

SanBio's long-term strategy includes:

Growth Opportunities

Market Potential:

• Large patient populations with TBI and stroke
• Limited treatment options for chronic deficits
• Growing acceptance of regenerative medicine

• Additional neurological indications under evaluation
• Combination therapy approaches with rehabilitation
• Next-generation cell products in development
• Geographic expansion opportunities

Challenges

Development Risks:

• Regulatory pathway in other markets
• Manufacturing scale-up
• Reimbursement challenges
• Competition from other approaches

• Maintaining product quality at scale
• Supply chain management
• Skilled workforce requirements
• Regulatory compliance across jurisdictions

Clinical Development Results

TBI Trial Results Summary

Phase 1/2a Results:
The initial clinical trial demonstrated:

• Favorable safety profile at all dose levels
• Evidence of neurological improvement in treated patients
• Dose-dependent response observed
• Effects maintained at long-term follow-up

• Primary efficacy endpoint met in modified analysis
• Clinically meaningful improvements in motor function
• Improvements observed across multiple assessment tools
• Benefits sustained through 12-month follow-up

Stroke Trial Results Summary

Phase 2 Results:

• Safety profile confirmed in stroke population
• Signals of efficacy observed in motor recovery
• Subgroup analyses suggest benefit in certain patient populations
• Data support further development in stroke indication

Biomarker Findings

Imaging Biomarkers:

• MRI evidence of structural changes in some patients
• No concerning findings indicative of tumor formation
• Post-treatment changes consistent with repair mechanisms

• Neurotrophic factor levels measurable post-treatment
• Inflammatory marker changes consistent with immunomodulation
• No concerning safety signals in biomarker profiles

Market Access and Reimbursement

Japanese Market

Reimbursement Framework:

• Established pricing methodology for regenerative medicine products
• Consideration of value-based pricing
• Review by relevant Japanese authorities

• Launch through specialized hospital networks
• Reimbursement discussions with Japanese payors
• Patient access programs

International Markets

US Market Considerations:

• FDA regulatory pathway evaluation
• Pricing and reimbursement strategy development
• Market size and opportunity assessment

• EMA regulatory engagement
• EU market access strategy
• Pricing and reimbursement across member states

Manufacturing Excellence

Quality Management

SanBio maintains robust quality management systems:

Quality Assurance:

• GMP-compliant manufacturing
• Rigorous quality control testing
• Comprehensive documentation
• Regular audits and inspections

• Japanese pharmaceutical regulations
• International harmonization where applicable
• Continuous improvement programs

Production Capacity

Manufacturing Infrastructure:

• Dedicated manufacturing facility in Japan
• Capacity for commercial production
• Quality control laboratories
• Storage and distribution capabilities

Competitive Positioning

Market Opportunity

The addressable market for SB623 includes:

Traumatic Brain Injury:

• Significant patient population with chronic deficits
• Limited treatment options currently available
• High unmet medical need

• Large patient population globally
• Significant burden of post-stroke disability
• No approved disease-modifying therapies

Strategic Advantages

SanBio's Position:

• First-mover in Japanese cell therapy for neurological conditions
• Proprietary technology platform
• Established safety and efficacy data
• Strong IP portfolio
• Experienced leadership team

Future Development Roadmap

Near-term Priorities

Medium-term Goals

Long-term Vision

SanBio's long-term vision includes:

• Becoming a global leader in regenerative medicine for CNS disorders
• Expanding into additional therapeutic areas
• Developing innovative platforms beyond cell therapy
• Creating sustainable value for patients and shareholders

Research Publications

Key Publications

SanBio's research has been published in peer-reviewed journals:

Clinical Publications:

• Phase 1/2a TBI trial results
• Phase 2 stroke trial results
• Long-term follow-up data

• Mechanism of action studies
• Animal model efficacy
• Safety and toxicology

Conference Presentations

SanBio presents at major conferences:

• Society for Neuroscience
• American Academy of Neurology
• International Society for Stem Cell Research
• Japanese neurological conferences

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Traumatic Brain Injury](/diseases/traumatic-brain-injury)
• [Stroke](/diseases/stroke)
• [Mesenchymal Stem Cells](/cell-types/mesenchymal-stem-cells)
• [Regenerative Medicine](/therapeutics/regenerative-medicine)
• [Cell Therapy](/therapeutics/cell-therapy)
• [Japanese Pharmaceutical Companies](/companies/japanese-pharmaceutical)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [BDNF](/proteins/bdnf)
• [GDNF](/proteins/gdnf)

External Links

• [SanBio Official Website](https://www.sanbio.com/en/)
• [SanBio Company Overview](https://www.sanbio.com/en/)
• [SB623 Product Information](https://www.sanbio.com/en/)
• [AKUUGO Product Approval (2025)](https://www.sanbio.com/en/)
• [ClinicalTrials.gov - SB623 TBI](https://clinicaltrials.gov)
• [ClinicalTrials.gov - SB623 Stroke](https://clinicaltrials.gov)
• [PubMed - MSC Research](https://pubmed.ncbi.nlm.nih.gov/)
• [ScienceDirect - Regenerative Medicine](https://www.sciencedirect.com/)
• [ScienceDirect - Cell Therapy](https://www.sciencedirect.com/)
• [PubMed - TBI Research](https://pubmed.ncbi.nlm.nih.gov/)
• [PubMed - Stroke Research](https://pubmed.ncbi.nlm.nih.gov/)
• [PubMed - Neural Repair](https://pubmed.ncbi.nlm.nih.gov/)
• [PMDA - Japanese Regulations](https://www.pmda.go.jp/)
• [Tokyo Stock Exchange](https://www.jpx.co.jp/)
• [Japan Biotechnology Association](https://www.jba.or.jp/)
• [Japanese Regenerative Medicine Society](https://www.jsrm.jp/)
• [Nature - Stem Cell Research](https://www.nature.com/)

References